Contents

Search

lindane (Kwell, Scabene)

Tradename: Kwell, Scabene. Indications: - refractory scabies - pediculosis (Lice) Contraindications: - acutely inflamed skin or raw, weeping surfaces Caution: Do not use in pregnant or nursing mothers, infants or small children because of reports of neurotoxicity & teratogenicity. Dosage: 1) refractory scabies: a) apply 30 mL of 1% cream or lotion. b) wash after 8-12 hours c) 2 treatments 1 week apart (not ovicidal). 2) Lice: 1% shampoo 30 mL/application. 3) apply a thin layer of lotion & massage it on the skin from the neck to the toes 4) adults: bathe & remove drug after 8-12 hours 5) children: wash off after 6 hours of application Lotion: 1% (60 mL, 473 mL) Pharmacokinetics: - skin & adipose tissue may act as repositories for the drug Adverse effects: - uncommon (< 1%) - dizziness, restlessness, ataxia, seizures*, headache, eczema, contact dermatitis, nausea/vomiting, aplastic anemia, hepatitis, hematuria, pulmonary edema - 60% increased risk for non-Hodgkin's lymphoma [6] * FDA black box warning [5] banned in California Laboratory: - lindane in air - lindane in water - lindane in blood - lindane in serum/plasma - lindane in urine

Interactions

drug interactions

General

antiparasitic agent

Properties

MISC-INFO: pregnancy-category B safety in lactation ?

Database Correlations

PUBCHEM cid=727

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 992
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  4. Geriatrics Review Syllabus, American Geriatrics Society, 5th edition, 2002-2004
  5. Prescriber's Letter 10(5):28 2003
  6. World Health Organization (WHO). Press Release. June 2015 International Agency for Research on Cancer. IARC Monographs evaluate DDT, lindane, and 2,4-D http://www.iarc.fr/en/media-centre/pr/2015/pdfs/pr236_E.pdf